{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:32:16Z","timestamp":1790839936605,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002426","name":"Fondazione Telethon","doi-asserted-by":"publisher","award":["GSP16001"],"award-info":[{"award-number":["GSP16001"]}],"id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002426","name":"Fondazione Telethon","doi-asserted-by":"publisher","award":["GUP09004"],"award-info":[{"award-number":["GUP09004"]}],"id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EJPRD","award":["GENOMIT"],"award-info":[{"award-number":["GENOMIT"]}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2016-02361495"],"award-info":[{"award-number":["RF-2016-02361495"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To assess natural history and 12-month change of a series of scales and functional outcome measures in a cohort of 117 patients with primary mitochondrial myopathy (PMM).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Twelve months follow-up data of 117 patients with PMM were collected. We analysed the 6-min walk test (6MWT), timed up-and-go test (\u00d7\u20093) (3TUG), five-times sit-to-stand test (5XSST), timed water swallow test (TWST), and test of masticating and swallowing solids (TOMASS) as functional outcome measures; the Fatigue Severity Scale and West Haven-Yale Multidimensional pain inventory as patient-reported outcome measures. PMM patients were divided into three phenotypic categories: mitochondrial myopathy (MiMy) without extraocular muscles involvement, pure chronic progressive external ophthalmoplegia (PEO) and PEO&amp;MiMy. As 6MWT is recognized to have significant test\u2013retest variability, we calculated MCID (minimal clinically important difference) as one third of baseline 6\u00a0min walking distance (6MWD) standard deviation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At 12-month follow-up, 3TUG, 5XSST and FSS were stable, while TWST and the perceived pain severity (WHYMPI) worsened. 6MWD significantly increased in the entire cohort, especially in the higher percentiles and in PEO patients, while was substantially stable in the lower percentile (&lt;\u2009408\u00a0m) and MiMy patients. This increase in 6MWD was considered not significant, as inferior to MCID (33.3\u00a0m). NMDAS total score showed a slight but significant decline at 12\u00a0months (0.9 point). The perceived pain severity significantly worsened. Patients with PEO performed better in functional measures than patients with PEO&amp;MiMy or MiMy, and had lower values of NMDAS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>PMM patients showed a slow global decline valued by NMDAS at 12\u00a0months; 6MWT was a more reliable measurement below 408\u00a0m, substantially stable at 12\u00a0months. PEO patients had better motor performance and lower NMDAS than PEO&amp;MiMy and MiMy also at 12\u00a0months of follow-up.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-022-11324-3","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T06:02:41Z","timestamp":1660802561000},"page":"6555-6565","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Primary mitochondrial myopathy: 12-month follow-up results of an Italian cohort"],"prefix":"10.1007","volume":"269","author":[{"given":"V.","family":"Montano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lopriore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gruosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Carelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. P.","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Filosto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lamperti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Mongini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Musumeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Servidei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tonin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Toscano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Primiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. L.","family":"Valentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bortolani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Marchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Modenese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cotti Piccinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Risi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Meneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. G.","family":"Arena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Siciliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2738-8562","authenticated-orcid":false,"given":"Michelangelo","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"key":"11324_CR1","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.nmd.2017.08.006","volume":"27","author":"M Mancuso","year":"2017","unstructured":"Mancuso M, McFarland R, Klopstock T et al (2017) International workshop: outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adults. Consensus recommendations. 16\u201318 November 2016, Rome, Italy. Neuromuscul Disord 27:1126\u20131137. https:\/\/doi.org\/10.1016\/j.nmd.2017.08.006","journal-title":"Neuromuscul Disord"},{"key":"11324_CR2","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000519","author":"V Montano","year":"2020","unstructured":"Montano V, Gruosso F, Carelli V et al (2020) Primary mitochondrial myopathy: clinical features and outcome measures in 118 cases from Italy. Neurol Genet. https:\/\/doi.org\/10.1212\/NXG.0000000000000519","journal-title":"Neurol Genet"},{"key":"11324_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/J.RMED.2020.105933","author":"SJ Halliday","year":"2020","unstructured":"Halliday SJ, Wang L, Yu C et al (2020) Six-minute walk distance in healthy young adults. Respir Med. https:\/\/doi.org\/10.1016\/J.RMED.2020.105933","journal-title":"Respir Med"},{"key":"11324_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/CELLS11030334","author":"KG Claeys","year":"2022","unstructured":"Claeys KG, D\u2019hondtFache AL et al (2022) Six-minute walk distance is a useful outcome measure to detect motor decline in treated late-onset Pompe disease patients. Cells. https:\/\/doi.org\/10.3390\/CELLS11030334","journal-title":"Cells"},{"key":"11324_CR5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/MUS.27543","volume":"65","author":"C Tard","year":"2022","unstructured":"Tard C, Bayot M, Davion J et al (2022) Factors impacting performance on the 6-minute walk test by people with late-onset Pompe disease. Muscle Nerve 65:693\u2013697. https:\/\/doi.org\/10.1002\/MUS.27543","journal-title":"Muscle Nerve"},{"key":"11324_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/MUS.23902","volume":"48","author":"CM Mcdonald","year":"2013","unstructured":"Mcdonald CM, Henricson EK, Abresch RT et al (2013) The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve 48:343\u2013356. https:\/\/doi.org\/10.1002\/MUS.23902","journal-title":"Muscle Nerve"},{"key":"11324_CR7","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/S00415-017-8567-Z","volume":"264","author":"D Orsucci","year":"2017","unstructured":"Orsucci D, Angelini C, Bertini E et al (2017) Revisiting mitochondrial ocular myopathies: a study from the Italian Network. J Neurol 264:1777\u20131784. https:\/\/doi.org\/10.1007\/S00415-017-8567-Z","journal-title":"J Neurol"},{"key":"11324_CR8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008861","author":"KL Madsen","year":"2020","unstructured":"Madsen KL, Buch AE, Cohen BH et al (2020) Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy (MOTOR trial). Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000008861","journal-title":"Neurology"},{"key":"11324_CR9","doi-asserted-by":"publisher","first-page":"E1212","DOI":"10.1212\/WNL.0000000000005255","volume":"90","author":"A Karaa","year":"2018","unstructured":"Karaa A, Haas R, Goldstein A et al (2018) Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology 90:E1212\u2013E1221. https:\/\/doi.org\/10.1212\/WNL.0000000000005255","journal-title":"Neurology"},{"key":"11324_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/crt2.41","volume":"6","author":"J Flickinger","year":"2021","unstructured":"Flickinger J, Fan J, Wellik A et al (2021) Development of a mitochondrial myopathy-composite assessment tool. JCSM Clin Rep 6:109\u2013127. https:\/\/doi.org\/10.1002\/crt2.41","journal-title":"JCSM Clin Rep"},{"key":"11324_CR11","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ANA.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell JR, Rodino-Klapac LR, Sahenk Z et al (2013) Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 74:637\u2013647. https:\/\/doi.org\/10.1002\/ANA.23982","journal-title":"Ann Neurol"},{"key":"11324_CR12","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","volume":"92","author":"BT Darras","year":"2019","unstructured":"Darras BT, Chiriboga CA, Iannaccone ST et al (2019) Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies. Neurology 92:e2492\u2013e2506. https:\/\/doi.org\/10.1212\/WNL.0000000000007527","journal-title":"Neurology"},{"key":"11324_CR13","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","volume":"20","author":"J Diaz-Manera","year":"2021","unstructured":"Diaz-Manera J, Kishnani PS, Kushlaf H et al (2021) Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurol 20:1012\u20131026. https:\/\/doi.org\/10.1016\/S1474-4422(21)00241-6","journal-title":"Lancet Neurol"},{"key":"11324_CR14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/1750-1172-8-160","volume":"8","author":"R Lachmann","year":"2013","unstructured":"Lachmann R, Schoser B (2013) The clinical relevance of outcomes used in late-onset Pompe disease: can we do better? Orphanet J Rare Dis 8:160. https:\/\/doi.org\/10.1186\/1750-1172-8-160","journal-title":"Orphanet J Rare Dis"},{"key":"11324_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/S13023-018-0848-9","author":"JW Witherspoon","year":"2018","unstructured":"Witherspoon JW, Vasavada RP, Waite MR et al (2018) 6-minute walk test as a measure of disease progression and fatigability in a cohort of individuals with RYR1-related myopathies. Orphanet J Rare Dis. https:\/\/doi.org\/10.1186\/S13023-018-0848-9","journal-title":"Orphanet J Rare Dis"},{"key":"11324_CR16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","volume":"10","author":"R Jaeschke","year":"1989","unstructured":"Jaeschke R, Singer J, Guyatt GH (1989) Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 10:407\u2013415. https:\/\/doi.org\/10.1016\/0197-2456(89)90005-6","journal-title":"Control Clin Trials"},{"key":"11324_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/ana.25506","volume":"86","author":"C Dom\u00ednguez-Gonz\u00e1lez","year":"2019","unstructured":"Dom\u00ednguez-Gonz\u00e1lez C, Madruga-Garrido M, Mavillard F et al (2019) Deoxynucleoside therapy for thymidine kinase 2-deficient myopathy. Ann Neurol 86:293\u2013303. https:\/\/doi.org\/10.1002\/ana.25506","journal-title":"Ann Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11324-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11324-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11324-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T12:06:12Z","timestamp":1667131572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11324-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["11324"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11324-3","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,18]]},"assertion":[{"value":"8 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no disclosures relevant to the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Written informed consent was obtained from all participants, and the ethics committees of each center approved the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Standard protocol approvals, registrations, and patient consents"}},{"value":"All authors agreed to the publication of the manuscript in its current form.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}